Regulatory Blog

The US Food and Drug Administration (FDA) has announced its Fiscal Year (FY) 2027 Generic Drug User Fee Amendments (GDUFA) Science and Research Priority Initiatives. The guidance outlines eight research areas intended to address scientific challenges in generic drug development, improve the efficiency of bioequivalence assessments, and accelerate patient access to generic medicines. The priorities were identified through collaboration with industry and public stakeholders, in